Systematic review of evidence on feasibility of administering intranasal live attenuated influenza vaccine at home

In the United States, influenza vaccination coverage in adults and children remains below target, with disparities across racial and ethnic groups and setting urbanicity. Reducing barriers to influenza vaccination may improve coverage. Live attenuated influenza vaccine (LAIV) recently gained United States Food and Drug Administration approval for a Supplemental Biologics License for self- or caregiver administration. A systematic literature search of Embase and Medline (PubMed) was conducted on March 6, 2025. Of the 144 articles identified and reviewed for relevance, five articles reported effectiveness, safety, practicality, or preference data for self- or caregiver administration of LAIV (SA-LAIV). In the relevant studies, SA‑LAIV appeared to have comparable safety and effectiveness to healthcare professional-administered LAIV and was often the preferred method of vaccine administration by patients. At-home annual influenza vaccination may be a better option for some individuals and families, which could improve vaccination accessibility.